Logo image of ERF.PA

EUROFINS SCIENTIFIC (ERF.PA) Stock Fundamental Analysis

Europe - EPA:ERF - FR0014000MR3 - Common Stock

60.62 EUR
+0.02 (+0.03%)
Last: 10/30/2025, 5:35:15 PM
Fundamental Rating

6

Taking everything into account, ERF scores 6 out of 10 in our fundamental rating. ERF was compared to 20 industry peers in the Life Sciences Tools & Services industry. While ERF belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. ERF may be a bit undervalued, certainly considering the very reasonable score on growth These ratings would make ERF suitable for value investing!


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

ERF had positive earnings in the past year.
ERF had a positive operating cash flow in the past year.
ERF had positive earnings in each of the past 5 years.
Each year in the past 5 years ERF had a positive operating cash flow.
ERF.PA Yearly Net Income VS EBIT VS OCF VS FCFERF.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

1.2 Ratios

ERF has a Return On Assets (3.54%) which is comparable to the rest of the industry.
ERF's Return On Equity of 8.09% is fine compared to the rest of the industry. ERF outperforms 65.00% of its industry peers.
ERF has a Return On Invested Capital of 9.79%. This is amongst the best in the industry. ERF outperforms 85.00% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ERF is in line with the industry average of 7.43%.
The last Return On Invested Capital (9.79%) for ERF is above the 3 year average (8.70%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 3.54%
ROE 8.09%
ROIC 9.79%
ROA(3y)3.79%
ROA(5y)5.05%
ROE(3y)7.94%
ROE(5y)10.72%
ROIC(3y)8.7%
ROIC(5y)10.54%
ERF.PA Yearly ROA, ROE, ROICERF.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

ERF has a Profit Margin (5.44%) which is in line with its industry peers.
In the last couple of years the Profit Margin of ERF has grown nicely.
ERF has a Operating Margin of 15.59%. This is comparable to the rest of the industry: ERF outperforms 60.00% of its industry peers.
In the last couple of years the Operating Margin of ERF has grown nicely.
ERF's Gross Margin of 23.29% is on the low side compared to the rest of the industry. ERF is outperformed by 80.00% of its industry peers.
ERF's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 15.59%
PM (TTM) 5.44%
GM 23.29%
OM growth 3Y-11.93%
OM growth 5Y3.56%
PM growth 3Y-23.05%
PM growth 5Y9.75%
GM growth 3Y-7.6%
GM growth 5Y1.83%
ERF.PA Yearly Profit, Operating, Gross MarginsERF.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20 25

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ERF is creating some value.
Compared to 1 year ago, ERF has less shares outstanding
The number of shares outstanding for ERF has been increased compared to 5 years ago.
The debt/assets ratio for ERF has been reduced compared to a year ago.
ERF.PA Yearly Shares OutstandingERF.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
ERF.PA Yearly Total Debt VS Total AssetsERF.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

ERF has an Altman-Z score of 2.67. This is not the best score and indicates that ERF is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.67, ERF is in line with its industry, outperforming 50.00% of the companies in the same industry.
The Debt to FCF ratio of ERF is 5.25, which is a neutral value as it means it would take ERF, 5.25 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 5.25, ERF is doing good in the industry, outperforming 75.00% of the companies in the same industry.
A Debt/Equity ratio of 0.77 indicates that ERF is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.77, ERF is doing worse than 60.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.77
Debt/FCF 5.25
Altman-Z 2.67
ROIC/WACC1.29
WACC7.61%
ERF.PA Yearly LT Debt VS Equity VS FCFERF.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.3 Liquidity

ERF has a Current Ratio of 1.26. This is a normal value and indicates that ERF is financially healthy and should not expect problems in meeting its short term obligations.
ERF has a Current ratio of 1.26. This is comparable to the rest of the industry: ERF outperforms 45.00% of its industry peers.
ERF has a Quick Ratio of 1.19. This is a normal value and indicates that ERF is financially healthy and should not expect problems in meeting its short term obligations.
ERF's Quick ratio of 1.19 is fine compared to the rest of the industry. ERF outperforms 75.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.26
Quick Ratio 1.19
ERF.PA Yearly Current Assets VS Current LiabilitesERF.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 16.50% over the past year.
The Earnings Per Share has been growing by 18.34% on average over the past years. This is quite good.
Looking at the last year, ERF shows a small growth in Revenue. The Revenue has grown by 2.53% in the last year.
The Revenue has been growing by 8.78% on average over the past years. This is quite good.
EPS 1Y (TTM)16.5%
EPS 3Y-21.42%
EPS 5Y18.34%
EPS Q2Q%19.61%
Revenue 1Y (TTM)2.53%
Revenue growth 3Y1.14%
Revenue growth 5Y8.78%
Sales Q2Q%5.64%

3.2 Future

ERF is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.34% yearly.
The Revenue is expected to grow by 7.27% on average over the next years.
EPS Next Y14.76%
EPS Next 2Y14.31%
EPS Next 3Y14.14%
EPS Next 5Y13.34%
Revenue Next Year5.44%
Revenue Next 2Y5.6%
Revenue Next 3Y6.01%
Revenue Next 5Y7.27%

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
ERF.PA Yearly Revenue VS EstimatesERF.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2B 4B 6B 8B 10B
ERF.PA Yearly EPS VS EstimatesERF.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1 2 3 4 5

7

4. Valuation

4.1 Price/Earnings Ratio

ERF is valuated correctly with a Price/Earnings ratio of 16.84.
Based on the Price/Earnings ratio, ERF is valued cheaper than 85.00% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.76. ERF is valued slightly cheaper when compared to this.
With a Price/Forward Earnings ratio of 15.02, ERF is valued correctly.
Based on the Price/Forward Earnings ratio, ERF is valued cheaper than 85.00% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.63, ERF is valued a bit cheaper.
Industry RankSector Rank
PE 16.84
Fwd PE 15.02
ERF.PA Price Earnings VS Forward Price EarningsERF.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ERF is valued cheaply inside the industry as 90.00% of the companies are valued more expensively.
ERF's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ERF is cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 14.08
EV/EBITDA 8.47
ERF.PA Per share dataERF.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of ERF may justify a higher PE ratio.
A more expensive valuation may be justified as ERF's earnings are expected to grow with 14.14% in the coming years.
PEG (NY)1.14
PEG (5Y)0.92
EPS Next 2Y14.31%
EPS Next 3Y14.14%

4

5. Dividend

5.1 Amount

With a yearly dividend of 0.96%, ERF is not a good candidate for dividend investing.
ERF's Dividend Yield is rather good when compared to the industry average which is at 0.69. ERF pays more dividend than 85.00% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.31, ERF's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.96%

5.2 History

On average, the dividend of ERF grows each year by 16.51%, which is quite nice.
Dividend Growth(5Y)16.51%
Div Incr Years1
Div Non Decr Years1
ERF.PA Yearly Dividends per shareERF.PA Yearly Dividends per shareYearly Dividends per share 2018 2021 2022 2023 2024 2025 0.2 0.4 0.6 0.8

5.3 Sustainability

54.91% of the earnings are spent on dividend by ERF. This is a bit on the high side, but may be sustainable.
ERF's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP54.91%
EPS Next 2Y14.31%
EPS Next 3Y14.14%
ERF.PA Yearly Income VS Free CF VS DividendERF.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B
ERF.PA Dividend Payout.ERF.PA Dividend Payout, showing the Payout Ratio.ERF.PA Dividend Payout.PayoutRetained Earnings

EUROFINS SCIENTIFIC

EPA:ERF (10/30/2025, 5:35:15 PM)

60.62

+0.02 (+0.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)10-21 2025-10-21
Earnings (Next)01-28 2026-01-28/amc
Inst Owners37.21%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap11.04B
Revenue(TTM)6.89B
Net Income(TTM)374.80M
Analysts68.89
Price Target65.1 (7.39%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.96%
Yearly Dividend0.52
Dividend Growth(5Y)16.51%
DP54.91%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)7.84%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-0.46%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.26%
Revenue NY rev (3m)-0.82%
Valuation
Industry RankSector Rank
PE 16.84
Fwd PE 15.02
P/S 1.6
P/FCF 14.08
P/OCF 8.4
P/B 2.38
P/tB N/A
EV/EBITDA 8.47
EPS(TTM)3.6
EY5.94%
EPS(NY)4.04
Fwd EY6.66%
FCF(TTM)4.3
FCFY7.1%
OCF(TTM)7.22
OCFY11.91%
SpS37.84
BVpS25.45
TBVpS-3.69
PEG (NY)1.14
PEG (5Y)0.92
Graham Number45.4
Profitability
Industry RankSector Rank
ROA 3.54%
ROE 8.09%
ROCE 12.64%
ROIC 9.79%
ROICexc 10.74%
ROICexgc 34.1%
OM 15.59%
PM (TTM) 5.44%
GM 23.29%
FCFM 11.37%
ROA(3y)3.79%
ROA(5y)5.05%
ROE(3y)7.94%
ROE(5y)10.72%
ROIC(3y)8.7%
ROIC(5y)10.54%
ROICexc(3y)9.52%
ROICexc(5y)11.6%
ROICexgc(3y)31.02%
ROICexgc(5y)39.55%
ROCE(3y)11.31%
ROCE(5y)13.7%
ROICexgc growth 3Y-18.17%
ROICexgc growth 5Y3.78%
ROICexc growth 3Y-15.5%
ROICexc growth 5Y6.63%
OM growth 3Y-11.93%
OM growth 5Y3.56%
PM growth 3Y-23.05%
PM growth 5Y9.75%
GM growth 3Y-7.6%
GM growth 5Y1.83%
F-Score7
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 0.77
Debt/FCF 5.25
Debt/EBITDA 2.1
Cap/Depr 84.94%
Cap/Sales 7.7%
Interest Coverage 9.93
Cash Conversion 77.37%
Profit Quality 209.21%
Current Ratio 1.26
Quick Ratio 1.19
Altman-Z 2.67
F-Score7
WACC7.61%
ROIC/WACC1.29
Cap/Depr(3y)89.21%
Cap/Depr(5y)85.64%
Cap/Sales(3y)8.63%
Cap/Sales(5y)7.99%
Profit Quality(3y)162.79%
Profit Quality(5y)158.88%
High Growth Momentum
Growth
EPS 1Y (TTM)16.5%
EPS 3Y-21.42%
EPS 5Y18.34%
EPS Q2Q%19.61%
EPS Next Y14.76%
EPS Next 2Y14.31%
EPS Next 3Y14.14%
EPS Next 5Y13.34%
Revenue 1Y (TTM)2.53%
Revenue growth 3Y1.14%
Revenue growth 5Y8.78%
Sales Q2Q%5.64%
Revenue Next Year5.44%
Revenue Next 2Y5.6%
Revenue Next 3Y6.01%
Revenue Next 5Y7.27%
EBIT growth 1Y14.03%
EBIT growth 3Y-10.93%
EBIT growth 5Y12.66%
EBIT Next Year86.11%
EBIT Next 3Y30.34%
EBIT Next 5Y22%
FCF growth 1Y113.13%
FCF growth 3Y-7.69%
FCF growth 5Y25.62%
OCF growth 1Y31.31%
OCF growth 3Y-4.44%
OCF growth 5Y14.24%

EUROFINS SCIENTIFIC / ERF.PA FAQ

What is the ChartMill fundamental rating of EUROFINS SCIENTIFIC (ERF.PA) stock?

ChartMill assigns a fundamental rating of 6 / 10 to ERF.PA.


Can you provide the valuation status for EUROFINS SCIENTIFIC?

ChartMill assigns a valuation rating of 7 / 10 to EUROFINS SCIENTIFIC (ERF.PA). This can be considered as Undervalued.


Can you provide the profitability details for EUROFINS SCIENTIFIC?

EUROFINS SCIENTIFIC (ERF.PA) has a profitability rating of 7 / 10.


How financially healthy is EUROFINS SCIENTIFIC?

The financial health rating of EUROFINS SCIENTIFIC (ERF.PA) is 5 / 10.


Is the dividend of EUROFINS SCIENTIFIC sustainable?

The dividend rating of EUROFINS SCIENTIFIC (ERF.PA) is 4 / 10 and the dividend payout ratio is 54.91%.